Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.

Antunes, Liliana;Rojas-Castro, Madelyn;Lozano, Marcos;Martínez-Baz, Iván;Bourgeois, Marc;et.al.
(2025) Influenza and Other Respiratory Viruses — Vol. 19, n° 3, p. e70081 (2025)

Files

AntunesLInfluenzaOtherRespirViruses2025.pdf
  • Open Access
  • Adobe PDF
  • 490.75 KB
Download

Details

Authors
  • Antunes, Lilianaorcid-logo
    Author
  • Rojas-Castro, Madelynorcid-logo
    Author
  • Lozano, Marcos
    Author
  • Martínez-Baz, Iván
    Author
  • Delaere, BénédicteUCLouvain
    Collaborator
  • Bourgeois, MarcUCLouvain
    Collaborator
Show more
Abstract
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Antunes, L., Rojas-Castro, M., Lozano, M., Martínez-Baz, I., Leroux-Roels, I., Borg, M.-L., Oroszi, B., Fitzgerald, M., Dürrwald, R., Jancoriene, L., Machado, A., Petrović, G., Lazar, M., Součková, L., Bacci, S., Howard, J., Verdasca, N., Basile, L., Castilla, J., et al. (2025). Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and Other Respiratory Viruses, 19(3), e70081. https://doi.org/10.1111/irv.70081 (Original work published 2025)